Christopher Chow, MD
Internal Medicine · Northridge, CANPI 1528024122
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 609 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 54 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 609 payments — averaging $20.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Daiichi Sankyo Inc.$1K
- Amgen$891
- Johnson & Johnson$846
- Lilly USA, LLC$785
- Boehringer Ingelheim$574
- plus $6K from 48 others
Across 1,835 payments — averaging $5091.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$7.7M
- American Regent$826K
- Novo Nordisk AS$689K
- Astellas Pharma Global Development$67K
- Alnylam Pharmaceuticals Inc.$49K
- Gilead$7K
What the payments were for
- Food & beverage$12,43599%
- Education$1171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,552 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 83 | $102,860 |
| OzempicSemaglutide | 76 | $76,612 |
| EliquisApixaban | 44 | $55,499 |
| JardianceEmpagliflozin | 42 | $52,914 |
| FarxigaDapagliflozin Propanediol | 30 | $32,444 |
| RexultiBrexpiprazole | 16 | $26,742 |
| VascepaIcosapent Ethyl | 24 | $18,031 |
| BenicarOlmesartan Medoxomil | 18 | $16,441 |
| MyrbetriqMirabegron | 26 | $15,818 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $14,070 |
| DapagliflozinDapagliflozin Propanediol | 14 | $11,814 |
| Diclofenac Sodium | 58 | $11,539 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $10,615 |
| XareltoRivaroxaban | 12 | $8,413 |
| MeloxicamMeloxicam, Submicronized | 19 | $7,611 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $785 | $102,86083 claims |
| Novo NordiskOzempic | $217 | $76,61276 claims |
| PfizerEliquis, Premarin, Paxlovid | $449 | $64,257105 claims |
| Boehringer IngelheimJardiance | $574 | $52,91442 claims |
| AstraZenecaFarxiga | $471 | $32,44430 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $314 | $26,74216 claims |
| Daiichi Sankyo Inc.Benicar | $1,381 | $16,44118 claims |
| Astellas Pharma US IncMyrbetriq | $216 | $15,81826 claims |
| GSKTrelegy Ellipta | $426 | $10,61512 claims |
| Johnson & JohnsonXarelto | $846 | $8,41312 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $205 | $7,08112 claims |
| AbbVieSynthroid | $2,383 | $6,31868 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Northridge
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.